Adcentrx Therapeutics gets FDA IND approval for advanced solid tumours treatment
The IND clearance represents a crucial step in the drug's clinical development journey, allowing Adcentrx Therapeutics to move…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
18 Jul 23
The IND clearance represents a crucial step in the drug's clinical development journey, allowing Adcentrx Therapeutics to move…
18 Jul 23
These recommendations, which have been developed through the Executive Steering Group on Shortages and Safety of Medicinal Products…
18 Jul 23
Healthcare-associated infections (HAI), also known as hospital-acquired infections, are a major problem healthcare systems face worldwide. Each year,…
18 Jul 23
The disinterested members of the Pardes Board of Directors have unanimously determined that the acquisition by Purchaser is…
17 Jul 23
Versanis’ lead asset, bimagrumab is a monoclonal antibody, currently being developed in the BELIEVE Phase 2b study, as…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
17 Jul 23
The approval was based on findings from a Phase 1 study, as well as results from the Phase…
17 Jul 23
Xpovio is said to be the first authorised selective inhibitor of the XPO1 in the world that promotes…
17 Jul 23
In the trial, ACU193 met the primary and secondary objectives in both single and multiple doses in 60…
17 Jul 23
The grant is intended to support the further development of CTR-107 (Noregen), a novel regenerative therapeutic designed to…
17 Jul 23
GHz-Class NMR, Structural Biology assisted by Artificial Intelligence, a New Scientific Software Division and Innovative Helium Solutions at…